Literature DB >> 12490494

Power rolloff during interactive radiofrequency ablation can enhance necrosis when treating hepatocellular carcinoma.

Shi-Ming Lin1, Chun-Jung Lin, Hock-Jean Chung, Chao-Wei Hsu, Cheng-Yuan Peng.   

Abstract

OBJECTIVE: The purpose of this study was to compare the efficacy between standard and interactive radiofrequency ablation for treatment of hepatocellular carcinoma. SUBJECTS AND METHODS: Of 97 patients with 112 nodular hepatocellular carcinomas, 59 hepatocellular carcinomas were ablated using a standard algorithm and 53 hepatocellular carcinomas, using an interactive algorithm. For the procedure using the interactive algorithm, the electrode's array was partially retracted or fully deployed depending on the change of impedance. Complete tumor necrosis was defined as the lack of enhancement on single-detector helical CT at least 4 months after the last radiofrequency ablation.
RESULTS: Complete necrosis was achieved in 101 (90%) of 112 hepatocellular carcinomas, with complete necrosis being achieved more frequently in hepatocellular carcinomas undergoing interactive ablation (96%) than standard ablation (85%) (p = 0.034). Power rolloff (a clinical end point in which power decreases as impedance increases) occurred in all of the 53 hepatocellular carcinomas that underwent interactive ablation, whereas power rolloff occurred in 48 (81%) of the 59 hepatocellular carcinomas that underwent standard ablation (p = 0.00053). Complete necrosis occurred more frequently when rolloff was achieved (96%) than without rolloff (36%) (p < 0.0001). Multivariate analysis determined that power rolloff was an independent factor in achieving complete necrosis of hepatocellular carcinomas (p < 0.0001).
CONCLUSION: The use of interactive radiofrequency ablation increased the frequency of power rolloff and the rate of complete necrosis in the treatment of hepatocellular carcinoma. Power rolloff was a significant determinant of whether complete necrosis was achieved in hepatocellular carcinomas treated with radiofrequency ablation.

Entities:  

Mesh:

Year:  2003        PMID: 12490494     DOI: 10.2214/ajr.180.1.1800151

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  7 in total

1.  Maximizing parameters for tissue ablation by using an internally cooled electrode.

Authors:  John P McGahan; Shaun Loh; Fernando J Boschini; Eric E Paoli; John M Brock; Wayne L Monsky; Chin-Shang Li
Journal:  Radiology       Date:  2010-06-08       Impact factor: 11.105

2.  Radiofrequency ablation for hepatocellular carcinoma: use of low vs maximal radiofrequency power.

Authors:  T C Macatula; C-C Lin; C-J Lin; W-T Chen; S-M Lin
Journal:  Br J Radiol       Date:  2011-03-22       Impact factor: 3.039

Review 3.  Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors.

Authors:  Stefaan Mulier; Yicheng Ni; Jacques Jamart; Theo Ruers; Guy Marchal; Luc Michel
Journal:  Ann Surg       Date:  2005-08       Impact factor: 12.969

4.  Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less.

Authors:  S-M Lin; C-J Lin; C-C Lin; C-W Hsu; Y-C Chen
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

Review 5.  Local ablation for hepatocellular carcinoma in taiwan.

Authors:  Shi-Ming Lin
Journal:  Liver Cancer       Date:  2013-04       Impact factor: 11.740

6.  Percutaneous radiofrequency ablation versus surgical radiofrequency ablation for malignant liver tumours: the long-term results.

Authors:  John Wong; Kit-Fai Lee; Simon Chun-Ho Yu; Paul Sing-Fun Lee; Yue-Sun Cheung; Ching-Ning Chong; Philip Ching-Tak Ip; Paul Bo-San Lai
Journal:  HPB (Oxford)       Date:  2012-11-28       Impact factor: 3.647

7.  Comparative evaluation of percutaneous laser and radiofrequency ablation in patients with HCC smaller than 4 cm.

Authors:  Antonio Orlacchio; Francesca Bolacchi; Fabrizio Chegai; Alberto Bergamini; Elisa Costanzo; Costantino Del Giudice; Mario Angelico; Giovanni Simonetti
Journal:  Radiol Med       Date:  2013-11-26       Impact factor: 3.469

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.